Arisaph Pharmaceuticals Overview
- Year Founded
-
1999
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Arisaph Pharmaceuticals General Information
Description
Developer of therapies for cardiometabolic diseases and cancer. The company utilizes drug discovery platforms to develop differentiated medicines that act selectively on validated targets.
Contact Information
Website
www.arisaph.comCorporate Office
- 155 Federal Street
- Suite 1602
- Boston, MA 02110
- United States
Corporate Office
- 155 Federal Street
- Suite 1602
- Boston, MA 02110
- United States
Arisaph Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 17-Mar-2017 | Completed | Out of Business | |||
| 4. Later Stage VC (Series H) | 21-Dec-2015 | Completed | Generating Revenue | |||
| 3. Grant | 01-Jan-2014 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series G) | 01-Nov-2013 | $10M | $26M | Completed | Generating Revenue | |
| 1. Later Stage VC (Series F) | 05-Aug-2006 | $16M | $16M | Completed | Generating Revenue |
Arisaph Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series H | ||||||||
| Series G | ||||||||
| Series F | ||||||||
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 300,000 | $0.100000 | $3.33 | $3.33 | 1x | $3.33 | 2.86% | |
| Series A | 300,000 | $0.100000 | $6.67 | $6.67 | 1x | $6.25 | 3.05% |
Arisaph Pharmaceuticals Comparisons
Industry
Financing
Details
Arisaph Pharmaceuticals Competitors (1)
One of Arisaph Pharmaceuticals’s competitors is Cambrex, a Private Equity-Backed company based in East Rutherford, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cambrex | Private Equity-Backed | East Rutherford, NJ |
Arisaph Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Arisaph Pharmaceuticals Patents
Arisaph Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2802952-A1 | Niacin mimetics, and methods of use thereof | Inactive | 24-Jun-2010 | ||
| AU-2015203711-A1 | Niacin mimetics, and methods of use thereof | Active | 24-Jun-2010 | ||
| AU-2011270726-A1 | Niacin mimetics, and methods of use thereof | Active | 24-Jun-2010 | ||
| AU-2011270726-B2 | Niacin mimetics, and methods of use thereof | Inactive | 24-Jun-2010 | ||
| AU-2011270726-C1 | Niacin mimetics, and methods of use thereof | Inactive | 24-Jun-2010 | A61K31/5377 |
Arisaph Pharmaceuticals FAQs
-
When was Arisaph Pharmaceuticals founded?
Arisaph Pharmaceuticals was founded in 1999.
-
Where is Arisaph Pharmaceuticals headquartered?
Arisaph Pharmaceuticals is headquartered in Boston, MA.
-
What industry is Arisaph Pharmaceuticals in?
Arisaph Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Arisaph Pharmaceuticals a private or public company?
Arisaph Pharmaceuticals is a Private company.
-
What is Arisaph Pharmaceuticals’s current revenue?
The current revenue for Arisaph Pharmaceuticals is .
-
How much funding has Arisaph Pharmaceuticals raised over time?
Arisaph Pharmaceuticals has raised $28.5M.
-
Who are Arisaph Pharmaceuticals’s competitors?
Cambrex is a competitor of Arisaph Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
